METHODS OF TREATING CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER USING SCLEROSTIN ANTAGONISTS

摘要

The disclosure relates to method for treating Chronic kidney disease (CKD) with evidence of Mineral and Bone Disorder (MBD), including patients having a diagnosis of CKD-MBD, e.g., stage 3-5 CKD patients (e.g., CKD-5D patients) having renal osteodystrophy (ROD), preferably adynamic bone disease (ABD), by antagonizing Sclerostin expression, secretion, signaling and/or function, e.g, using an anti-sclerostin antibody or antigen binding fragment therof (e.g., Antibody 1).